Drug Type Chemical drugs |
Synonyms BIO 030, BIO030, Bio 30 |
Target |
Action inhibitors, modulators |
Mechanism PAK1 inhibitors(p21 (RAC1) activated kinase 1 inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Fatigue Syndrome, Chronic | Phase 2 | United States | - | - |
| Fatigue Syndrome, Chronic | Phase 2 | - | - | |
| Glioma | Preclinical | United States | 01 May 2009 | |
| Glioma | Preclinical | Japan | 01 May 2009 | |
| Glioma | Preclinical | - | 01 May 2009 | |
| Neurofibromatoses | Preclinical | United States | 01 May 2009 | |
| Neurofibromatoses | Preclinical | Japan | 01 May 2009 | |
| Neurofibromatoses | Preclinical | - | 01 May 2009 |





